Tricks of the TradeTrump's Second TermMy EconomyI've Always Wondered ...

Loading...

0:00
0% played
Support the fact-based journalism you rely on with a donation to Marketplace today. Give Now!
Stories Tagged as

Drug costs

Election 2024

Health care tops list of voters' economic worries

by Mitchell Hartman
Feb 22, 2024
While inflation is moderating, some health-related costs are still climbing.
Health care affordability and inflation are top concerns for voters this year.
Alex Wong/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Medicare to start negotiating prices for 10 drugs in 2024

by Lily Jamali
Dec 29, 2023
But drug companies are trying to stymie the effort with a raft of lawsuits.
Medicare’s ability to negotiate drug prices will apply to just 10 medications for now, including treatments for heart disease and diabetes.
stevecoleimages/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Who will end up paying the price for Biogen's new Alzheimer's drug?

by Kimberly Adams
Jun 18, 2021
The cost of the newly approved treatment will be about $56,000 a year, much of it paid for by Medicare.
Biogen’s new Alzheimer's treatment drug, Aduhelm, has an annual sticker price of $56,000.
Dominick Reuter/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Cancer death rates have fallen 27 percent

by Andy Uhler
Jan 9, 2019
Oncology experts say advances in cancer drugs have played a major role.
Cathy Bradley says many cancer patients stay at work because they need the health insurance their employer provides.
Justin Sullivan/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Deals aimed at reining in costs of cancer drugs show promise

by Dan Gorenstein
Jun 6, 2016
Some manufacturers are willing to tie drug price to performance.
Dr. Julie Brahmer (R) and Katie Thornton review PET (Positron Emission Tomography) scans of a patient being treated at the Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. 
Win McNamee/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Cigna deal calls for rebates if drugs don't perform

by Dan Gorenstein
May 11, 2016
It's the seventh such deal for the insurance giant, which is putting pressure on drug makers in an effort to keep costs down.
Rosemary Petty, a Publix Supermarket pharmacy technician, counts out a prescription August 7, 2007 in Miami, Florida. 
Joe Raedle/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

FTC fights against new strategy for delaying generics

by Dan Gorenstein
Apr 1, 2016
FTC files case against drug maker for deals cut with two generic firms that extend its monopoly
John Moore/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE

For public good, not for profit.

Donate

Why rare-disease treatments can be big business

by Annie Baxter
Jan 11, 2016
Combined, Shire and Baxalta expect 65 percent of total revenue to come from rare disease treatments.
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Police turn to pricey rehab drug for offenders

by Miles Bryan
Nov 4, 2015
The drug, administered once a month, helps ensure patient compliance.
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Valeant: how aggressively can a drug company sell

by Mitchell Hartman
Oct 30, 2015
Valeant is under scrutiny for its business practices.
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE